PNC Financial Services Group
EIDX

PNC Financial Services Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

PNC Financial Services Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,120
Closed -$148K – 4287
2020
Q4 		$148K Sell
1,120
-2,060
-65% -$182K ﹤0.01% 2261
2020
Q3 		$160K Buy
+3,180
New +$143K ﹤0.01% 2054

PNC Financial Services Group's EIDX Position: Q1 2021 in Review

PNC Financial Services Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 1,120 shares — an estimated $148K sold.

PNC Financial Services Group first reported a position in EIDX in Q3 2020 and held it in 2 quarters. The position peaked at $160K in Q3 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • PNC Financial Services Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • PNC Financial Services Group sold 1,120 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $148K.
  • PNC Financial Services Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • PNC Financial Services Group's Eidos Therapeutics, Inc. Common Stock position peaked at $160K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on PNC Financial Services Group's 13F filing for Q1 2021, filed 7 May 2021.